Kiadis Pharma announces change to management board
11 Dezembro 2019 - 1:45PM
Kiadis Pharma announces change to management board
Amsterdam, The Netherlands, December 11,
2019 – Kiadis Pharma N.V. (“Kiadis” or the “Company”) (Euronext
Amsterdam and Brussels: KDS), a clinical stage
biopharmaceutical company, today announces that Scott A. Holmes,
the Company’s chief financial officer and member of the Company’s
management board, is stepping down to pursue other opportunities.
Mr. Holmes’ resignation will be effective December 31, 2019.
“I want to thank Scott for his contributions to
Kiadis; on behalf of the supervisory board and myself, we wish
Scott well in his future endeavors,” Arthur Lahr, CEO of Kiadis
commented. “Following our recent restructuring, Kiadis is an
earlier stage company with a strong management team to advance our
Company through our next phase of growth. As such, we do not plan
to fill the CFO role as Scott’s responsibilities can be taken over
by other management team members, specifically Amy Sullivan and
Paul van Hagen.”
Ms. Sullivan joined Kiadis in January 2019 as
SVP, corporate affairs and has been promoted to Kiadis’ chief
strategy officer responsible for fundraising, investor relations,
public affairs and corporate communications. Mr. van Hagen joined
Kiadis in 2018 as VP, finance, has been promoted to SVP finance,
and will continue to be responsible for the finance function.
About KiadisFounded in 1997,
Kiadis Pharma is building a fully integrated biopharmaceutical
company committed to developing innovative therapies for patients
with life-threatening diseases. With headquarters in Amsterdam, the
Netherlands, and offices and activities across the United States,
Kiadis Pharma is reimagining medicine by leveraging the natural
strengths of humanity and our collective immune system to source
the best cells for life.
Kiadis Pharma is listed on the regulated market
of Euronext Amsterdam and Euronext Brussels since July 2, 2015,
under the symbol KDS. Learn more at kiadis.com.
Kiadis Contacts:
Kiadis Pharma:
Maryann Cimino, Manager, Corporate AffairsTel: +1 (617)
710-7305m.cimino@kiadis.com |
Optimum Strategic
Communications:Mary Clark, Supriya Mathur, Hollie VileTel:
+44 203 950 9144David Brilleslijper (Amsterdam)Tel: +31 610 942
514kiadis@optimumcomms.com |
Forward Looking Statements
Certain statements, beliefs and opinions in this press release are
forward-looking, which reflect Kiadis Pharma’s or, as appropriate,
Kiadis Pharma’s officers’ current expectations and projections
about future events. By their nature, forward-looking statements
involve a number of known and unknown risks, uncertainties and
assumptions that could cause actual results, performance,
achievements or events to differ materially from those expressed,
anticipated or implied by the forward-looking statements. These
risks, uncertainties and assumptions could adversely affect the
outcome and financial effects of the plans and events described
herein. A multitude of factors including, but not limited to,
changes in demand, regulation, competition and technology, can
cause actual events, performance, achievements or results to differ
significantly from any anticipated or implied development.
Forward-looking statements contained in this press release
regarding past trends or activities should not be taken as a
representation that such trends or activities will continue in the
future. As a result, Kiadis Pharma expressly disclaims any
obligation or undertaking to release any update or revisions to any
forward-looking statements in this press release as a result of any
change in expectations or projections, or any change in events,
conditions, assumptions or circumstances on which these
forward-looking statements are based. Neither Kiadis Pharma nor its
advisers or representatives nor any of its subsidiary undertakings
or any such person’s officers or employees guarantees that the
assumptions underlying such forward-looking statements are free
from errors nor does either accept any responsibility for the
future accuracy of the forward-looking statements contained in this
press release or the actual occurrence of the anticipated or
implied developments. You should not place undue reliance on
forward-looking statements, which speak only as of the date of this
press release.